Impact of COVID-19 on business activities and performance
First written in FY2021-Q1. 3 of 15 entries say "Worsened", first in FY2021-Q3. Latest entry: FY2026.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2026RestatedAnnual report
「The Group has implemented thorough measures tailored to the spread of infectious diseases to prevent infection. If the spread of infectious diseases persists for an extended period, the number of prescriptions in the dispensing pharmacy business may decline due to reduced patient visits to medical institutions, the healthcare business may see users refrain from using home-visit and day-care services because of concerns about infection risk, and sales activities in the pharmaceutical wholesaling business may be restricted, potentially affecting the Group’s business results.」
The disclosure continues to use a framework that describes infectious diseases in general and their impact on each business, rather than focusing on COVID-19. - FY2025Wording changed from focusing on COVID-19 to infectious diseases generallyAnnual report
「The Group has implemented thorough measures tailored to the spread of infectious diseases to prevent infection. If the spread of infectious diseases persists for an extended period, the number of prescriptions in the dispensing pharmacy business may decline due to reduced patient visits to medical institutions, the healthcare business may see users refrain from using home-visit and day-care services because of concerns about infection risk, and sales activities in the pharmaceutical wholesaling business may be restricted, potentially affecting the Group’s business results.」
The wording has shifted from focusing on COVID-19 to describing risks related to infectious diseases in general and their impact on each business. - FY2024-Q3RestatedAnnual report
「With COVID-19 reclassified as a Class 5 infectious disease, some restrictions on conduct at facilities have been eased, but basic infection-control measures will continue for the time being, while the Group maintains an environment in which users of nursing care services can use the facilities with confidence, and」
The report describes the partial easing of restrictions on conduct following the reclassification of COVID-19 as a Class 5 infectious disease, together with the continuation of basic infection-control measures and efforts to ensure user safety. - FY2024-Q2RestatedAnnual report
「With COVID-19 reclassified as a Class 5 infectious disease, some restrictions on conduct at facilities have been eased, but basic infection-control measures will continue for the time being,」
The report describes the partial easing of restrictions on conduct following the reclassification of COVID-19 as a Class 5 infectious disease, together with the continuation of basic infection-control measures. - FY2024-Q1MitigatedAnnual report
「With COVID-19 reclassified as a Class 5 infectious disease, some restrictions on conduct at facilities were eased, but basic infection-control measures will continue for the time being, while the Group maintains an environment in which users of nursing care services can use the facilities with confidence, and」
The report describes the partial easing of restrictions on conduct following the reclassification of COVID-19 as a Class 5 infectious disease. While the previous effects have eased to some extent, infection-control measures continue. - FY2023WorsenedAnnual report
「Clusters of COVID-19 occurred intermittently at multiple day-care nursing facilities and other facilities throughout the consolidated fiscal year. As a result, utilization rates declined, partly because new users, particularly of day-care services, refrained from using them.」
The effects of the infection continued throughout the fiscal year, resulting in lower utilization in the healthcare business and an operating loss of ¥28 million, compared with operating profit of ¥218 million in the same period of the previous year. - FY2023-Q3WorsenedAnnual report
「In the healthcare business, multiple clusters of COVID-19 occurred during the first half at day-care nursing facilities and other facilities. As a result, utilization rates declined, partly because new users, particularly of day-care services, refrained from using them, and consolidated revenue and profit for the six-month period ended 30 September fell below the initial forecasts. Although infections temporarily subsided thereafter, clusters have recently occurred at multiple facilities again as the eighth wave spread.」
Clusters at multiple facilities led new users to refrain from using services and caused utilization rates to decline, while further clusters occurred as the eighth wave spread again. Operating profit in the healthcare business fell 84.3% year on year. - FY2023-Q2Containment of cluster effects alongside deterioration in performanceAnnual report
「In the healthcare business, clusters of COVID-19 at day-care nursing facilities and multiple other facilities during the first quarter reduced utilization rates, mainly at day-care services, compared with the previous period. The effects of the clusters had largely subsided recently, and the Group is working to provide nursing care services that enable all facility users to spend their time safely and comfortably. As a result, revenue was ¥3,901 million, down 0.9% year on year, and operating profit was ¥34 million, down 76.2%.」
Clusters actually occurred during the first quarter, leading to lower utilization at day-care services and a 76.2% decline in operating profit, while the report states that the effects of the clusters had largely subsided recently. - FY2023-Q1Partial easing of infection-related effects alongside the impact of facility clustersAnnual report
「In the healthcare business, the sixth wave of COVID-19 had peaked and the number of infections had stabilized. However, the Group continued to face a situation requiring caution, with a pronounced impact on performance caused by clusters that occurred at some operating facilities between March and April of this year.」
The report describes an improvement in the external environment as the sixth wave of infections peaked and the number of infections stabilized, while clusters at operating facilities affected performance, with recovery and continuing adverse effects occurring simultaneously. - FY2022-Q3Recovery progressing alongside concerns over the Omicron variantAnnual report
「The fifth wave of COVID-19 was moving toward containment, and the state of emergency was lifted at the end of September of the previous year. As restrictions on visits to medical institutions continued to ease, the number of prescriptions filled at existing stores exceeded the year-earlier level.」
While some effects eased, including the easing of restrictions on visits to medical institutions and the recovery in prescriptions filled at existing stores, the report also describes heightened concern over infection due to the spread of the Omicron variant and a slow economic recovery. - FY2022-Q2MitigatedAnnual report
「In the dispensing pharmacy business, the environment remained challenging due to the renewed spread of COVID-19, but restrictions on visits to medical institutions were gradually easing, and the number of prescriptions filled at existing stores had exceeded the year-earlier level since March.」
Although the effects of COVID-19 remain, the report describes easing restrictions on visits to medical institutions and a recovery in the number of prescriptions filled at existing stores, indicating some signs of improvement in the impact on the dispensing pharmacy business. - FY2022-Q1MitigatedAnnual report
「In the dispensing pharmacy business, the environment remained challenging due to the effects of COVID-19, but there were signs that restrictions on visits to medical institutions were gradually easing, and the number of prescriptions filled was on a recovery trend.」
Although the effects of COVID-19 remain, the report describes easing restrictions on visits to medical institutions and a recovery trend in the number of prescriptions filled, indicating some signs of improvement in the impact on the dispensing pharmacy business. Patients' reluctance to use healthcare services and restrictions on pharmaceutical wholesalers' sales activities continued. - FY2021-Q3WorsenedAnnual report
「The effects of COVID-19 have persisted, resulting in a continued challenging business environment.」
The effects of COVID-19 have persisted. In dispensing pharmacies, the number of prescriptions filled has declined as patients refrain from visiting medical institutions; in healthcare, users have continued to refrain from using services; and in pharmaceutical wholesaling, restrictions on outpatient care and sales activities have continued. The accounting disclosures also state that losses may arise if the effects differ from expectations. - FY2021-Q2MaterialisedAnnual report
「In the dispensing pharmacy business, the number of prescriptions filled declined due to reduced visits to medical institutions and other effects associated with the spread of COVID-19.」
Reduced visits to medical institutions due to COVID-19 resulted in fewer prescriptions filled, leading to lower revenue and operating profit in the dispensing pharmacy business. Patients' reluctance to use nursing care services and restrictions on the sales activities of pharmaceutical wholesalers also continued. - FY2021-Q1First statedAnnual report
「The spread of COVID-19 reduced the number of patients visiting medical institutions and affected the number of prescriptions filled, resulting in lower revenue and profit. As a result, revenue was ¥5,580 million, down 3.8% year on year, and operating profit was ¥257 million, down 35.3%.」
In relation to COVID-19, the business risks section states that there are no new risks, while the operating results section describes the actual effects on business activities and performance, including fewer patients visiting medical institutions, patients refraining from using nursing care services and restrictions on the sales activities of pharmaceutical wholesalers.